Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Cazzola, Mario ^a,b   Calzetta, Luigino ^a   Puxeddu, Ermanno ^a,b   Ora, Josuel ^b   Facciolo, Francesco ^c   Rogliani, Paola ^a,b   Matera, Maria Gabriella ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Glycopyrronium bromide; Human bronchi; Indacaterol fumarate; Synergistic interaction

Indexed keywords

ACETYLCHOLINE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; CYCLIC AMP; FORSKOLIN; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; IBERIOTOXIN; INDACATEROL; ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLYCOPYRRONIUM; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

ACETYLCHOLINE RELEASE; ADULT; ARTICLE; BRONCHIOLE; BRONCHODILATATION; BRONCHUS; BRONCHUS MUCOSA; BRONCHUS TONE; CONTROLLED STUDY; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; AGED; BRONCHOCONSTRICTION; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PRIMARY CELL CULTURE; TIME FACTOR;

ACETYLCHOLINE; ADENYLYL CYCLASES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHI; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPITHELIAL CELLS; FEMALE; GLYCOPYRROLATE; HUMANS; IN VITRO TECHNIQUES; INDANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRIMARY CELL CULTURE; QUINOLONES; TIME FACTORS;

EID: 84973623311     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0386-8     Document Type: Article

References (65)

1. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21(1):101-8. doi: 10.4104/pcrj.2011.00102.
2. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med. 2014;35(1):191-201. doi: 10.1016/j.ccm.2013.10.005.
3. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-94. doi: 10.1183/09031936.00200212.
4. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209. doi: 10.1016/S2213-2600(13)70052-3.
5. Matera MG, Rogliani P, Rinaldi B, Cazzola M. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015;8(1):35-41. doi: 10.1586/17512433.2015.977256.
6. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavalda A, et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014;745:135-43. doi: 10.1016/j.ejphar.2014.10.025.
7. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD. 2015;12(2):175-81. doi: 10.3109/15412555.2014.922172.
8. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. doi: 10.1016/j.rmed.2015.08.005. Respir Med. 2015. doi: 10.1016/j.rmed.2015.08.005.
9. Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168-73. doi: 10.1016/j.ejphar.2015.05.020.
10. Pelaia G, Maselli R, Matera MG. Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium. Pharmacology. 2014;94(5-6):249-58. doi: 10.1159/000368986.
11. Panettieri Jr RA. Bronchodilators, receptors and cross-talk: together is better? DOI: 10.1080/00325481.2015.1080589. Postgrad Med. 2015(ahead-of-print):1-10.
12. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, et al. Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi. Am J Respir Cell Mol Biol. 2011. doi: 10.1165/rcmb.2011-0056OC.
13. Cazzola M, Calzetta L, Page CP, Rinaldi B, Capuano A, Matera MG. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol. 2011;45(4):704-10. doi: 10.1165/rcmb.2010-0306OC.
14. Matera MG, Calzetta L, Passeri D, Facciolo F, Rendina EA, Page C, et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol. 2011;163(8):1740-54. doi: 10.1111/j.1476-5381.2011.01339.x.
15. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15-23. doi: 10.1016/j.pupt.2015.03.007.
16. Fulcher ML, Gabriel S, Burns KA, Yankaskas JR, Randell SH. Well-differentiated human airway epithelial cell cultures. Methods Mol Med. 2005;107:183-206. doi:1-59259-861-7:183.
17. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, et al. The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Ther. 2013;26(3):325-31. doi: 10.1016/j.pupt.2013.01.002.
18. Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophoton Int. 2004;11(7):1081-8693.
19. Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol Ther. 2011;24(2):221-6. doi: 10.1016/j.pupt.2010.12.008.
20. Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulm Pharmacol Ther. 2009;22(6):478-82. doi:S1094-5539(09)00052-2.
21. Binks AP, Paydarfar D, Schachter SC, Guz A, Banzett RB. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol. 2001;127(2-3):125-33. doi:S0034568701002523.
22. Holland M, Langton PD, Standen NB, Boyle JP. Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle. Br J Pharmacol. 1996;117(1):119-29.
23. Bialecki RA, Stinson-Fisher C. KCa channel antagonists reduce NO donor-mediated relaxation of vascular and tracheal smooth muscle. Am J Physiol. 1995;268(1 Pt 1):L152-9.
24. Brayden JE, Nelson MT. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science. 1992;256(5056):532-5.
25. Corompt E, Bessard G, Lantuejoul S, Naline E, Advenier C, Devillier P. Inhibitory effects of large Ca2 + -activated K+ channel blockers on beta-adrenergic- and NO-donor-mediated relaxations of human and guinea-pig airway smooth muscles. Naunyn Schmiedebergs Arch Pharmacol. 1998;357(1):77-86.
26. Link E, Edelmann L, Chou JH, Binz T, Yamasaki S, Eisel U, et al. Tetanus toxin action: inhibition of neurotransmitter release linked to synaptobrevin proteolysis. Biochem Biophys Res Commun. 1992;189(2):1017-23.
27. Pierce EJ, Davison MD, Parton RG, Habig WH, Critchley DR. Characterization of tetanus toxin binding to rat brain membranes. Evidence for a high-affinity proteinase-sensitive receptor. Biochem J. 1986;236(3):845-52.
28. Rabasseda X, Blasi J, Marsal J, Dunant Y, Casanova A, Bizzini B. Tetanus and botulinum toxins block the release of acetylcholine from slices of rat striatum and from the isolated electric organ of Torpedo at different concentrations. Toxicon. 1988;26(4):329-36.
29. Mochida S, Poulain B, Weller U, Habermann E, Tauc L. Light chain of tetanus toxin intracellularly inhibits acetylcholine release at neuro-neuronal synapses, and its internalization is mediated by heavy chain. FEBS Lett. 1989;253(1-2):47-51.
30. Naline E, Bardou M, Devillier P, Molimard M, Dumas M, Chalon P, et al. Inhibition by SR 59119A of isoprenaline-, forskolin- and VIP-induced relaxation of human isolated bronchi. Pulm Pharmacol Ther. 2000;13(4):167-74. doi: 10.1006/pupt.2000.0246.S1094-5539(00)90246-3.
31. Motulsky H, Christopoulos A. Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. Oxford: Oxford University Press; 2004.
32. Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015. doi: 10.1016/j.ejphar.2015.04.042.
33. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414-23. doi: 10.1124/jpet.113.204644.
34. European Medicines Agency. EMEA/H/C/003755/0000. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003755/WC500151413.pdf. Accessed April 5, 2016. 2013.
35. US Food and Drug Administration. Utibron Neohaler safely and effectively. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207930s000lbl.pdf. Accessed April 5, 2016. 2015.
36. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable chronic obstructive pulmonary disease. Chest. 2016. doi: 10.1016/j.chest.2016.02.646.
37. Kume H, Fukunaga K, Oguma T. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and beta2-adrenergic intrinsic efficacy. Pharmacol Ther. 2015;156:75-89. doi: 10.1016/j.pharmthera.2015.09.004.
38. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res. 2003;4:2.
39. Shore S, Irvin CG, Shenkier T, Martin JG. Mechanisms of histamine-induced contraction of canine airway smooth muscle. J Appl Physiol Respir Environ Exerc Physiol. 1983;55(1 Pt 1):22-6.
40. Aizawa H, Inoue H, Miyazaki N, Hara N. Histamine-induced increase in isometric tension of smooth muscle is mediated by local vagus nerve in human bronchus. Respiration. 2000;67(6):652-6. doi:56295.
41. Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1-9.
42. Smit M, Zuidhof AB, Bos IST, Maarsingh H, Gosens R, Zaagsma J, et al. The bronchoprotective effect of olodaterol against histamine is synergistically enhanced and prolonged by tiotropium bromide. Am J Respir Crit Care Med. 2011;183:A1379.
43. Smit M, Zuidhof AB, Bos SIT, Maarsingh H, Gosens R, Zaagsma J, et al. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma. J Pharmacol Exp Ther. 2014;348(2):303-10.
44. Chandrasekera PC, Pippin JJ. The human subject: an integrative animal model for 21(st) century heart failure research. Am J Transl Res. 2015;7(9):1636-47.
45. Belvisi MG, Patel HJ, Takahashi T, Barnes PJ, Giembycz MA. Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br J Pharmacol. 1996;117(7):1413-20.
46. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2014;15(7):961-77. doi: 10.1517/14656566.2014.899581.
47. Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5(2):85-98. doi: 10.1177/2040622313518227.
48. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127(2):413-20. doi: 10.1038/sj.bjp.0702573.
49. Barnes PJ. Muscarinic receptor subtypes in airways. Eur Respir J. 1993;6(3):328-31.
50. Watson N, Barnes PJ, Maclagan J. Actions of methoctramine, a muscarinic M2 receptor antagonist, on muscarinic and nicotinic cholinoceptors in guinea-pig airways in vivo and in vitro. Br J Pharmacol. 1992;105(1):107-12.
51. Kajekar R, Rohde HK, Myers AC. The integrative membrane properties of human bronchial parasympathetic Ganglia neurons. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1927-32.
52. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008;154(8):1558-71. doi: 10.1038/bjp.2008.185.
53. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci. 2003;72(18-19):2055-61. doi:S0024320503000833.
54. Reinheimer T, Bernedo P, Klapproth H, Oelert H, Zeiske B, Racke K, et al. Acetylcholine in isolated airways of rat, guinea pig, and human: species differences in role of airway mucosa. Am J Physiol. 1996;270(5 Pt 1):L722-8.
55. Kummer W, Lips KS, Pfeil U. The epithelial cholinergic system of the airways. Histochem Cell Biol. 2008;130(2):219-34. doi: 10.1007/s00418-008-0455-2.
56. Wessler IK, Kirkpatrick CJ. The Non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther. 2001;14(6):423-34. doi: 10.1006/pupt.2001.0313.
57. Belvisi MG. Overview of the innervation of the lung. Curr Opin Pharmacol. 2002;2(3):211-5. doi:S1471489202001455.
58. Canning BJ, Fischer A. Neural regulation of airway smooth muscle tone. Respir Physiol. 2001;125(1-2):113-27. doi:S0034568700002085.
59. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc. 2004;1(4):345-51. doi: 10.1513/pats.200409-045MS.
60. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219-33. doi: 10.1111/j.1474-8673.2006.00368.x.
61. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol. 1992;262(4 Pt 1):L466-71.
62. Kume H, Graziano MP, Kotlikoff MI. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc Natl Acad Sci U S A. 1992;89(22):11051-5.
63. Laurent F, Michel A, Bonnet PA, Chapat JP, Boucard M. Evaluation of the relaxant effects of SCA40, a novel charybdotoxin-sensitive potassium channel opener, in guinea-pig isolated trachealis. Br J Pharmacol. 1993;108(3):622-6.
64. Snetkov VA, Hirst SJ, Twort CH, Ward JP. Potassium currents in human freshly isolated bronchial smooth muscle cells. Br J Pharmacol. 1995;115(6):1117-25.
65. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. Functional effects of 20-HETE on human bronchi: hyperpolarization and relaxation due to BKCa channel activation. Am J Physiol Lung Cell Mol Physiol. 2007;293(4):L1037-44. doi: 10.1152/ajplung.00145.2007.